IARC sets conditions for population H. pylori screening

The International Agency for Research on Cancer (IARC), the World Health Organization's cancer agency, issued globally applicable guidance in 2025 for adult population programs that test for and treat Helicobacter pylori to prevent stomach cancer. The report makes screening a health-system pathway with testing, treatment and follow-up rather than a one-time home check.

An IARC-led analysis published in 2015 estimated that chronic H. pylori infection accounts for 89 percent of non-cardia stomach cancers worldwide. That population-attributable fraction does not mean 89 percent of infected people will develop cancer, and it does not cover every cancer arising near the top of the stomach.

Urgent symptoms belong in a diagnostic pathway

Population screening is intended for people without warning symptoms. The United Kingdom's National Health Service advises clinical assessment for difficulty swallowing, an upper-abdominal lump, noticeable unintentional weight loss, or possible stomach cancer symptoms that worsen or do not improve after three weeks; vomiting for more than two days needs urgent advice.

Australia's government-funded Healthdirect service says vomiting blood or coffee-ground-like material, passing black tarry stool or a large amount of blood, or bleeding accompanied by weakness or lightheadedness requires emergency care. People outside Australia should use their local emergency service, and they should not wait for an H. pylori screening appointment.

These signs can have causes other than cancer, but a stool antigen or breath test cannot examine the stomach or identify a bleeding source. A negative H. pylori result or earlier successful eradication does not replace assessment of new warning symptoms.

Screening policy depends on local cancer burden

The World Gastroenterology Organisation's 2021 global guideline links mass test-and-treat programs to a high local burden of stomach cancer and enough resources to test, prescribe treatment and manage follow-up. It says cost, laboratory capacity, infection prevalence and antibiotic resistance differ too widely for one pathway to fit every country.

IARC's 2025 report similarly asks health systems to assess need and readiness before launching a population program. Invitation ages, payment, repeat-testing rules and referral routes therefore come from the program operating where care is received, not from a worldwide age cutoff.

The source article describes publicly funded testing in Taiwan from 2026 for people aged 45 to 74, limited to once in a lifetime. APPI News could not independently verify those eligibility and coverage details through an international authority or original research source, so this international guide does not present them as a confirmed national rule.

Breath and stool tests can identify active infection

IARC's 2025 testing chapter says population programs should use noninvasive methods such as the 13C-urea breath test or an H. pylori stool antigen test; a blood antibody test cannot reliably distinguish a current infection from one that has already cleared and cannot confirm eradication. Local validation, sample handling and the prevalence of infection all affect test performance.

The same guidance says proton pump inhibitors, antibiotics and bismuth-containing medicines can suppress H. pylori and produce a false-negative breath or stool result. It calls for a two-week interval without proton pump inhibitors and a four-week interval without antibiotics before testing, but anyone taking prescribed medicine should obtain instructions from the ordering service rather than stop treatment independently.

IARC says an H. pylori stool antigen assay can be offered in the same screening encounter as a fecal immunochemical test (FIT) for colorectal cancer. The tests answer different questions: H. pylori antigen indicates infection, while a positive FIT detects blood and prompts diagnostic follow-up rather than a cancer diagnosis.

A confirmed infection leads to treatment planning

The WGO guideline says H. pylori testing should be ordered only when treatment will be offered if active infection is confirmed. Eradication normally requires a clinician-prescribed combination of medicines, while the choice depends on local resistance data, allergies, earlier antibiotic exposure, treatment history and what is available in that country.

The guideline also says completing the prescribed course is a major determinant of success. A person who develops adverse effects should contact the prescriber for instructions rather than shorten the course, reuse a failed combination or substitute antibiotics without clinical review.

Population treatment also has a public-health cost because it increases antibiotic use. IARC's implementation report includes antibiotic stewardship, adverse-event monitoring, treatment completion and eradication rates among the measures a program needs to track.

Post-treatment testing checks whether eradication worked

IARC's testing chapter recommends confirming eradication with a 13C-urea breath test or stool antigen test at least four weeks after therapy ends. Blood antibody tests are unsuitable for this step because antibodies may remain after the bacteria are gone.

Successful treatment lowers future stomach cancer risk, but it does not reset risk to zero. The WGO guideline says people who already have gastric atrophy or intestinal metaplasia can retain a cancer risk after eradication, and decisions about endoscopic surveillance depend on the extent of those changes and other factors such as family history.

A negative test of cure answers whether active infection was detected under suitable testing conditions. It does not inspect the stomach lining, rule out an existing cancer or determine whether a person with precancerous changes can stop surveillance.

Children and pregnancy need separate pathways

A 2024 joint guideline from the European and North American pediatric gastroenterology societies says routine H. pylori testing is not indicated for children with functional abdominal pain, while reliable noninvasive screening may be used for a child with a first-degree relative who had stomach cancer. It also places diagnosis and treatment selection under pediatric clinical care rather than applying an adult population program.

IARC's population guidance is written for adults and does not set one testing or treatment route for pregnancy or breastfeeding. People who are pregnant or breastfeeding should discuss timing and medicine choices with a clinician instead of applying an adult eradication pathway on their own.

Regular medicines and chronic conditions can also change the plan, particularly when a test requires temporarily withholding acid-suppressing or antimicrobial medicines. The clinician or screening service needs to balance test accuracy against the reason the medicine was prescribed.

Transmission advice cannot replace testing

The US National Cancer Institute says H. pylori can spread through contact with stool, saliva or vomit and is often acquired during childhood, with infection more common in crowded settings and places with poor sanitation. Those routes do not establish whether a particular person is infected.

The international guidance reviewed for this report did not quantify how much using shared or separate serving utensils changes infection or stomach cancer risk. The source article's dining-specific advice is therefore not presented as a proven prevention measure, and household hygiene cannot substitute for a validated test.

Frequently asked questions

Does a positive H. pylori test mean stomach cancer?
No. A positive breath or stool antigen test indicates active infection, while diagnosing cancer requires a separate clinical assessment and may require endoscopy and biopsy.

Should every adult be screened?
No single worldwide age or interval applies. Population programs depend on local cancer burden, resources, test performance, treatment capacity and national policy.

Should a confirmed active infection be treated?
Global gastroenterology guidance says testing should be undertaken when treatment will be offered if active infection is confirmed. A clinician should select the regimen because antibiotic resistance, allergies, earlier treatment and local availability affect the choice.

How is eradication confirmed?
IARC recommends a 13C-urea breath test or stool antigen test at least four weeks after therapy. Medication timing affects accuracy, so the ordering service should provide instructions before the test.

Does eradication remove all future stomach cancer risk?
No. Risk can persist when gastric atrophy or intestinal metaplasia is already present, and some people need a separate endoscopic surveillance plan.

Can H. pylori testing and colorectal screening happen together?
Some programs can offer stool antigen testing alongside FIT in one screening encounter. The assays have different purposes, and each result follows its own clinical pathway.